Troxyca ER Approval History
- FDA approved: Yes (First approved August 19th, 2016)
- Brand name: Troxyca ER
- Generic name: naltrexone and oxycodone
- Dosage form: Extended-Release Capsules
- Company: Pfizer Inc.
- Treatment for: Pain
Troxyca ER (oxycodone hydrochloride and naltrexone hydrochloride) is an extended-release, abuse-deterrent, narcotic analgesic formulation for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment.
Troxyca ER capsules are formulated to be abuse-deterrent, and contain extended-release oxycodone pellets with a sequestered naltrexone core. The naltrexone remains sequestered while the capsules are taken as directed. If however, the pellets are crushed, the sequestered naltrexone is released and works to counteract the effects of oxycodone.
Troxyca ER capsules are taken orally every twelve hours. Possible side effects include constipation, nausea, sleepiness, vomiting, tiredness, headache, dizziness, and abdominal pain.
Development History and FDA Approval Process for Troxyca ER
Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.